gefitinib has been researched along with Insulin Resistance in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barra, NG; Cavallari, JF; Duggan, BM; Foley, KP; Schertzer, JD | 1 |
| Cavallari, JF; Duggan, BM; Foley, KP; Henriksbo, BD; Schertzer, JD; Tamrakar, AK | 1 |
| Li, YX; Sun, Q; Wang, H; Wang, SN | 1 |
3 other study(ies) available for gefitinib and Insulin Resistance
| Article | Year |
|---|---|
RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice.
Topics: Adiposity; Animals; Blood Glucose; Diet, High-Fat; Gefitinib; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Obesity; Protein Kinase Inhibitors; Receptor-Interacting Protein Serine-Threonine Kinase 2; Signal Transduction | 2020 |
Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Blood Glucose; Cell Wall; Cytokines; Endotoxins; Gefitinib; Inflammation; Insulin Resistance; Lipolysis; Macrophages; Mice; Mice, Inbred C57BL; Models, Biological; NF-kappa B; Peptides; Protein Kinase Inhibitors; Receptor-Interacting Protein Serine-Threonine Kinase 2; Receptor-Interacting Protein Serine-Threonine Kinases | 2017 |
[Gefitinib improves insulin sensitivity in Wistar diabetes rats models].
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gefitinib; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Phosphatidylinositol 3-Kinases; Quinazolines; Rats; Rats, Wistar | 2009 |